Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2598-2607

  Olsen, Elise A ^a   Whittaker, Sean ^b   Kim, Youn H ^c   Duvic, Madeleine ^f   Prince, H Miles ^g   Lessin, Stuart R ^h   Wood, Gary S ^j   Willemze, Rein ^k   Demierre, Marie France ^l   Pimpinelli, Nicola ^m   Bernengo, Maria Grazia ⁿ   Ortiz Romero, Pablo L ^o   Bagot, Martine ^q   Estrach, Teresa ^p   Guitart, Joan ^s   Knobler, Robert ^u   Sanches, José Antonio ^w   Iwatsuki, Keiji ^x   Sugaya, Makoto ^y   Dummer, Reinhard ^z   Pittelkow, Mark ^aa   Hoppe, Richard ^d   Parker, Sareeta ^ab   Geskin, Larisa ⁱ   Pinter Brown, Lauren ^e   Girardi, Michael ^ac   Burg, Günter ^z   Ranki, Annamari ^ad   Vermeer, Maartan ^k   Horwitz, Steven ^ae   Heald, Peter ^ac   Rosen, Steve ^t   Cerroni, Lorenzo ^v   Dreno, Brigette ^r   Vonderheid, Eric C ^af   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c STANFORD CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l BOSTON UNIVERSITY   (United States)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^p UNIVERSITY OF BARCELONA   (Spain)

^q SAINT LOUIS HOSPITAL   (France)

^r Team 12   (France)

^s NORTHWESTERN UNIVERSITY   (United States)

^t NORTHWESTERN UNIVERSITY   (United States)

^u MEDICAL UNIVERSITY OF VIENNA   (Austria)

^v MEDICAL UNIVERSITY OF GRAZ   (Austria)

^w UNIVERSITY OF SÃO PAULO   (Brazil)

^x OKAYAMA UNIVERSITY   (Japan)

^y UNIVERSITY OF TOKYO   (Japan)

^z UNIVERSITY OF ZURICH   (Switzerland)

^aa Mayo Clinic   (United States)

^ab EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad UNIVERSITY OF HELSINKI   (Finland)

^ae MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^af DEPARTMENT OF PATHOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARM; BLOOD; BUTTOCK; CANCER STAGING; CANCER THERAPY; CONSENSUS; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ERYTHEMA; FOOT; FOREARM; HAND; HEAD; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; INGUINAL REGION; LEG; LYMPH NODE; MEDICAL RESEARCH; MEDICAL SOCIETY; MYCOSIS FUNGOIDES; NECK; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEZARY SYNDROME; SKIN DEFECT; SKIN LYMPHOMA; SKIN MANIFESTATION; SKIN TUMOR; STANDARDIZATION; THIGH; TRUNK; UNITED STATES; VISCERA;

CLINICAL TRIALS AS TOPIC; HUMANS; LYMPH NODES; MYCOSIS FUNGOIDES; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SEZARY SYNDROME; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; VISCERA;

EID: 79959290992     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.0630     Document Type: Review

References (41)

1. Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722, 2007 (Pubitemid 47443880)
2. Willemze R, Jaffe ES, Burg G, et al: WHOEORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
3. Lutzner M, Edelson R, Schein P, et al: Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 83:534-552, 1975
4. Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857-866, 2003 (Pubitemid 36898920)
5. Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63:725-728, 1979
6. Pimpinelli N, Olsen EA, Santucci M, et al: Defining early mycosis fungoides. J Am Acad Dermatol 53:1053-1063, 2005 (Pubitemid 41677332)
7. Sacks H, Chalmers TC, Smith H Jr: Randomized versus historical controls for clinical trials. Am J Med 72:233-240, 1982 (Pubitemid 12191842)
8. Stevens SR, Ke MS, Parry EJ, et al: Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The severity-weighted assessment tool (SWAT). Arch Dermatol 138:42-48, 2002 (Pubitemid 34056233)
9. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001 (Pubitemid 32112849)
10. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007 (Pubitemid 47218059)
11. Rieger E, Smolle J, Hoedl S, et al: Morphometrical analysis of mycosis fungoides on paraffinembedded sections. J Cutan Pathol 16:7-13, 1989 (Pubitemid 19065871)
12. Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary results. N Engl J Med 316:297-303, 1987 (Pubitemid 17036377)
13. Vonderheid EC, Bernengo MG, Burg G, et al: Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95-106, 2002 (Pubitemid 34073484)
14. Duvic M, Martin AG, Kim Y, et al: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma. Arch Dermatol 137:581-593, 2001 (Pubitemid 32458440)
15. Duncan K, Heald P, Tallini G, et al: Utility of PCR amplification of T-cell receptor rearrangements in the definition of cutaneous T-cell lymphoma relapse. J Invest Dermatol 110:645, 1998
16. Gobbi PG, Broglia C, Carnevale Maffe G, et al: Lymphomatous superficial lymph nodes: Limitations of physical examination for accurate staging and response assessment. Haematologica 87:1151-1156, 2002 (Pubitemid 35397773)
17. Hopper KD, Kasales CJ, Van Slyke MA, et al: Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol 167:851-854, 1996 (Pubitemid 26322230)
18. Brenner DJ, Hall EJ: Computed tomography: An increasing source of radiation exposure. N Engl J Med 357:2277-2284, 2007 (Pubitemid 350190758)
19. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
20. Lewis E, Bernardino ME, Salvador PG, et al: Post-therapy CT-detected mass in lymphoma patients: Is it viable tissue? J Comput Assist Tomogr 6:792-795, 1982 (Pubitemid 12097825)
21. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
22. Sausville EA, Eddy JL, Makuch RW, et al: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: Definition of three distinctive prognostic groups. Ann Intern Med 109:372-382, 1988
23. Schechter GP, Sausville EA, Fischmann AB, et al: Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 69:841-849, 1987 (Pubitemid 17057466)
24. Vonderheid EC, Bernengo MG: The Sézary syndrome: Hematologic criteria. Hematol Oncol Clin North Am 17:1367-1389, 2003
25. Vonderheid EC, Pena J, Nowell P: Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging. Leuk Lymphoma 47:1841-1856, 2006
26. Bogen SA, Pelley D, Charif M, et al: Immunophenotypic identification of Sézary cells in peripheral blood. Am J Clin Pathol 106:739-748, 1996 (Pubitemid 27009491)
27. Bernengo MG, Novelli M, Quaglino P, et al: The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 144:125-135, 2001 (Pubitemid 32154603)
28. Jones D, Dang NH, Duvic M, et al: Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 115:885-892, 2001 (Pubitemid 32476716)
29. Kukel S, Reinhold U, Oltermann I, et al: Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin Exp Immunol 98:163-168, 1994
30. Reinhold U, Abken H: CD4+ CD7- T cells: A separate subpopulation of memory T cells? J Clin Immunol 17:265-271, 1997
31. Vonderheid EC, Bigler RD, Kotecha A, et al: Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome). J Invest Dermatol 117:654-662, 2001 (Pubitemid 32955594)
32. Harmon CB, Witzig TE, Katzmann JA, et al: Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 35:404-410, 1996
33. Dummer R, Nestle FO, Niederer E, et al: Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sézary syndrome. Arch Dermatol Res 291:307-311, 1999 (Pubitemid 29281318)
34. Gorochov G, Bachelez H, Cayuela JM, et al: Expression of V beta gene segments by Sézary cells. J Invest Dermatol 105:56-61, 1995
35. Steinhoff M, Schopp S, Assaf C, et al: Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sézary syndrome. Leuk Res 33:88-99, 2009
36. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
37. Borowitz MJ, Weidner A, Olsen EA, et al: Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: Cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. Leukemia 7:859-863, 1993 (Pubitemid 23210865)
38. Zackheim HS, Koh HK, Weinstock MA: Assessing clinical outcomes in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1021-1029, 1995
39. Demierre MF, Tien A, Miller D: Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 141:325-330, 2005 (Pubitemid 40365448)
40. Chren MM, Lasek RJ, Quinn LM, et al: Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol 107:707-713, 1996 (Pubitemid 26371086)
41. Chren MM, Lasek RJ, Sahay AP, et al: Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5:105-110, 2001 (Pubitemid 32588315)